Anixa Biosciences
ANIX
49 hedge funds and large institutions have $15.4M invested in Anixa Biosciences in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 2 closing their positions.
676% more call options, than puts
Call options by funds: $194K | Put options by funds: $25K
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
20% more funds holding
Funds holding: 41 → 49 (+8)
0.53% more ownership
Funds ownership: 11.33% → 11.86% (+0.53%)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
10% less capital invested
Capital invested by funds: $17.1M → $15.4M (-$1.73M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$150K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$144K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$134K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$121K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$178K |
| 2 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$57.7K |
| 3 |
Renaissance Technologies
New York
|
-$44.7K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$17.5K |
| 5 |
BlackRock
New York
|
-$15.8K |
ANIX Hedge Fund Activity: Q4 2022 in Review
49 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2022, worth a combined $15.4M — down 10% from $17.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ANIX positions and 2 closed out — a net gain of 8 holders — while 11 added to existing stakes and 12 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $150K. The largest seller was Millennium Management, exiting entirely with an estimated $178K sold.
- 49 institutional investors held Anixa Biosciences (ANIX) as of Q4 2022, up from 41 in Q3 2022.
- Funds reported $15.4M of Anixa Biosciences stock for Q4 2022, down 10% quarter-over-quarter.
- 10 funds opened new Anixa Biosciences positions in Q4 2022 and 2 closed out, a net change of +8 holders.
- The largest Anixa Biosciences buyer in Q4 2022 was Susquehanna International Group, an estimated $150K added.
- The largest Anixa Biosciences seller in Q4 2022 was Millennium Management, an estimated $178K sold.
Based on aggregated 13F filings for Q4 2022.